^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
01/20/2021
Excerpt:
Diffuse large B-Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY…Preferred Regimens…GDP (gemcitabine, dexamethasone, cisplatin) ± rituximab or (gemcitabine, dexamethasone, carboplatin) ± rituximab